Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up.
- Author:
Zhi-xiang CHENG
1
;
Shan-hua ZOU
;
Feng LI
;
Jun-min LI
;
Jian-min WANG
;
Fang-yuan CHEN
;
Jun-ning CAO
;
Chun WANG
;
Zheng WEI
;
Yun-feng CHENG
Author Information
- Publication Type:Clinical Trial
- MeSH: Aged; Antibodies, Monoclonal; administration & dosage; adverse effects; Antibodies, Monoclonal, Murine-Derived; adverse effects; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Cyclophosphamide; adverse effects; therapeutic use; Doxorubicin; adverse effects; therapeutic use; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; drug therapy; Male; Middle Aged; Prednisone; adverse effects; therapeutic use; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vincristine; adverse effects; therapeutic use
- From: Chinese Journal of Hematology 2012;33(4):257-260
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy, safety and prognostic impact of rituximab plus CHOP (R-CHOP) regimen on patients with diffuse large B-cell lymphoma (DLBCL), to access the impact of R-CHOP on patients' prognosis and to compare that with CHOP regimen.
METHODSFive hundred and seven newly diagnosed DLBCL patients were enrolled from Jan. 1, 2000 to May 1, 2010. Patients were administered with 6 cycles of CHOP or at least 4 cycles of R-CHOP treatments. Rituximab was administered intravenously on day 1 at a dose of 375 mg/m(2). The typical CHOP regimen include cyclophosphamide (750 mg/m(2), IV), doxorubicin (50 mg/m(2), IV) and vincristine (1.4 mg/m(2), IV, maximum 2 mg) and prednisone (60 - 100 mg, oral, day 3 - 7). The complete response (CR) rates, overall response (OR) rates, and side events of these 2 groups were compared.
RESULTSOf the 411 analyzable patients, 224 received CHOP regimen and 187 received R-CHOP regimen. CR rate for R-CHOP group and CHOP group was 77.01% and 71.43%, respectively. OR rate in R-CHOP group was higher than that in the CHOP group (95.19% vs 87.95%, P = 0.007). The median follow-up time of R-CHOP group was 28.1 months vs that of 35.2 months in CHOP group. There was significant difference in progression free survival (PFS) and overall survival (OS) between 2 groups (P = 0.018 and 0.034, respectively). At the end of follow-up, the estimated median PFS in R-CHOP group had not been reached, while that was 84.8 months in CHOP group. The median OS in both groups had not yet been reached. The adverse events in R-CHOP group were similar with that in CHOP group.
CONCLUSIONSR-CHOP is a safe and effective regimen for management of newly diagnosed DLBCL, with a better remission rate, PFS and OS.
